Liver resident memory for malaria

疟疾的肝脏驻留记忆

基本信息

  • 批准号:
    10542653
  • 负责人:
  • 金额:
    $ 5.9万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-11-23 至 2024-10-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Our R01 project supports NIAID’s mission to better understand, treat, and prevent infectious diseases by focusing on pre-erythrocytic malaria vaccine development. Vaccines that efficiently stop the Plasmodium sporozoite (spz) or liver stage provide complete protection against malarial disease and will enable eradication efforts. There are currently no FDA-approved malaria vaccines for use in humans although repeated dosing with intravenously-administered attenuated spz has shown sterile protection against challenge in multiple Phase 1-2 clinical trials. Recently, CD8+ T cells that reside in the liver (liver resident memory T cells or Trm cells) have been identified as key cell types in protection against liver stage infection. Vaccine strategies that increase liver Trm cells and can be readily adapted to clinical use are therefore critically needed. Such vaccines could bolster CD8+ T cell immunity and may result in T cell-focused vaccines that achieve durable, high-grade protection for persons in endemic and non-endemic regions. Our laboratory has developed a two-dose vaccine that increases liver Trm cells and achieves sterile protection. This approach requires only a single dose of spz. This project aims to provide pre-clinical support for development of this two-dose ‘prime-and-trap’ vaccine. The University of Washington (UW) will collaborate with established partners at Sanaria Inc. In Aim 1, we will evaluate biological and technical questions about the proposed vaccine regimen, including dose dependence, effects of spz cryopreservation, adjuvant effects, interference from pre-existing antibodies, and use of multiple DNA plasmids. In Aim 2, we will investigate the magnitude and degree of antigen spreading following vaccination, a phenomenon that could enhance protection in the liver. In Aim 3, we will evaluate the prime-and-trap vaccine in the P. knowlesi non-human primate (NHP) immunization-challenge model and demonstrate Trm cell targeting in a P. falciparum NHP model. Tolerability and toxicology endpoints will be obtained in NHP studies in preparation for future clinical studies. In summary, this project will optimize and assess a two-dose prime-and-trap vaccine rationally designed to elicit complete protection against the Plasmodium liver stage.
摘要 我们的R01项目支持NIAID的使命,即通过专注于 红细胞前疟疾疫苗的开发。有效阻止疟原虫子孢子(SPZ)或肝脏的疫苗 这一阶段提供了对疟疾的全面保护,并将使根除努力成为可能。目前没有 FDA批准的用于人类的疟疾疫苗,尽管静脉注射减毒后重复给药 在多个1-2期临床试验中,SPZ已显示出对挑战的无菌保护。最近,CD8+T细胞 在肝脏中(肝脏常驻记忆T细胞或Trm细胞)已被确定为保护肝脏免受肝脏损害的关键细胞类型 处于感染阶段。因此,增加肝脏Trm细胞并易于临床使用的疫苗策略 这是急需的。这种疫苗可以增强CD8+T细胞免疫,并可能导致以T细胞为重点的疫苗 为流行和非流行地区的人提供持久、高质量的保护。我们的实验室已经研制出一种 增加肝脏Trm细胞并实现无菌保护的两剂疫苗。这种方法只需要单剂。 对SPZ的影响。该项目旨在为这种两剂疫苗的开发提供临床前支持。这个 华盛顿大学(UW)将与Sanaria Inc.的现有合作伙伴合作。在Aim 1中,我们将评估 关于拟议疫苗方案的生物学和技术问题,包括剂量依赖性、SPZ的效果 冷冻保存、佐剂效应、预先存在的抗体的干扰,以及多个DNA质粒的使用。在AIM 2,我们将调查接种疫苗后抗原传播的大小和程度,这一现象可能 加强对肝脏的保护。在目标3中,我们将在诺氏疟原虫非人类中评估初选和诱捕疫苗。 灵长类(NHP)免疫-挑战模型,并在恶性疟原虫NHP模型中演示Trm细胞靶向。 耐受性和毒理学终点将在NHP研究中获得,为未来的临床研究做准备。在……里面 总结,这个项目将优化和评估一种合理设计的两剂初级和陷阱疫苗,以获得完全 对肝脏疟原虫阶段的保护。

项目成果

期刊论文数量(8)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Sex-Specific Differences in Cytokine Induction by the Glycolipid Adjuvant 7DW8-5 in Mice.
  • DOI:
    10.3390/biom13010008
  • 发表时间:
    2022-12-21
  • 期刊:
  • 影响因子:
    5.5
  • 作者:
    Watson, Felicia N. N.;Duncombe, Caroline J.;Kalata, Anya C. C.;Conrad, Ethan;Chakravarty, Sumana;Sim, B. Kim Lee;Hoffman, Stephen L. L.;Tsuji, Moriya J.;Shears, Melanie J.;Murphy, Sean C. C.
  • 通讯作者:
    Murphy, Sean C. C.
More time to kill: A longer liver stage increases T cell-mediated protection against pre-erythrocytic malaria.
  • DOI:
    10.1016/j.isci.2023.108489
  • 发表时间:
    2023-12-15
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Yadav, Naveen;Parthiban, Chaitra;Billman, Zachary P.;Stone, Brad C.;Watson, Felicia N.;Zhou, Kevin;Olsen, Tayla M.;Talavera, Irene Cruz;Seilie, Annette Mariko;Kalata, Anya C.;Matsubara, Jokichi;Shears, Melanie J.;Reynolds, Rebekah A.;Murphy, Sean C.
  • 通讯作者:
    Murphy, Sean C.
Ultra-low volume intradermal administration of radiation-attenuated sporozoites with the glycolipid adjuvant 7DW8-5 completely protects mice against malaria.
使用糖脂佐剂 7DW8-5 对辐射减毒子孢子进行超低容量皮内给药,可完全保护小鼠免受疟疾的侵害。
  • DOI:
    10.21203/rs.3.rs-3243319/v1
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Watson,FeliciaN;Shears,MelanieJ;Kalata,AnyaC;Duncombe,CarolineJ;Seilie,AMariko;Chavtur,Chris;Conrad,Ethan;Talavera,IreneCruz;Raappana,Andrew;Sather,DNoah;Chakravarty,Sumana;Sim,BKimLee;Hoffman,StephenL;Tsuji,Moriya;Mu
  • 通讯作者:
    Mu
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Sean C Murphy其他文献

Assessing the daily natural history of asymptomatic emPlasmodium/em infections in adults and older children in Katakwi, Uganda: a longitudinal cohort study
乌干达卡塔奎地区成年人和大龄儿童无症状疟原虫感染的每日自然史评估:一项纵向队列研究
  • DOI:
    10.1016/s2666-5247(23)00262-8
  • 发表时间:
    2024-01-01
  • 期刊:
  • 影响因子:
    20.400
  • 作者:
    Dianna E B Hergott;Tonny J Owalla;Weston J Staubus;Annette M Seilie;Chris Chavtur;Jennifer E Balkus;Bernadette Apio;Jimmy Lema;Barbara Cemeri;Andrew Akileng;Ming Chang;Thomas G Egwang;Sean C Murphy
  • 通讯作者:
    Sean C Murphy
Title: Implementing Selective Digestive Decontamination in the intensive care unit: A qualitative analysis of considerations identified by critical care nurses
标题:在重症监护病房实施选择性消化道净化:对重症监护护士确定的考虑因素进行定性分析
  • DOI:
  • 发表时间:
    2015
  • 期刊:
  • 影响因子:
    0
  • 作者:
    K. Kayentao;A. Ongoiba;Anne C Preston;Sara A. Healy;Zonghui Hu;Jeff Skinner;S. Doumbo;Jing Wang;H. Cisse;Didier Doumtabe;Abdrahamane Traoré;Hamadi Traore;Adama Djiguiba;Shanping Li;Mary E. Peterson;Shinyi Telscher;Azza H. Idris;William C Adams;Adrian B McDermott;S. Narpala;Bob C Lin;Leonid Serebryannyy;S. Hickman;Andrew J McDougal;Sandra Vazquez;Matthew Reiber;Judy A Stein;Jason G Gall;Kevin Carlton;P. Schwabl;Siriman Traore;Mamadou Keita;Amatigué Zéguimé;Adama Ouattara;M’Bouye Doucoure;Amagana Dolo;Sean C Murphy;D. E. Neafsey;S. Portugal;Abdoulaye A Djimde;B. Traore;Robert A. Seder;Peter D. Crompton
  • 通讯作者:
    Peter D. Crompton

Sean C Murphy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Sean C Murphy', 18)}}的其他基金

DDT-BMQ-0000100 Qualification of the Plasmodium falciparum 18S rRNA biomarker for malaria-endemic controlled human malaria infection studies
DDT-BMQ-0000100 疟疾流行控制人类疟疾感染研究中恶性疟原虫 18S rRNA 生物标志物的鉴定
  • 批准号:
    10836140
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure
整合人类和非人类灵长类动物数据,以了解在面对先前的疟疾暴露时获得红细胞前免疫力
  • 批准号:
    10343399
  • 财政年份:
    2022
  • 资助金额:
    $ 5.9万
  • 项目类别:
DDT-BMQ-0000107 Qualification of the Plasmodium falciparum 18S rRNA biomarker for malaria field studies
DDT-BMQ-0000107 用于疟疾现场研究的恶性疟原虫 18S rRNA 生物标志物的鉴定
  • 批准号:
    10616035
  • 财政年份:
    2022
  • 资助金额:
    $ 5.9万
  • 项目类别:
Integrating human and non-human primate data to understand the acquisition of pre-erythrocytic immunity in the face of previous malaria exposure
整合人类和非人类灵长类动物数据,以了解在面对先前的疟疾暴露时获得红细胞前免疫力
  • 批准号:
    10570273
  • 财政年份:
    2022
  • 资助金额:
    $ 5.9万
  • 项目类别:
Development of an oral liver-targeted prime-and-trap malaria vaccine
开发口服肝脏靶向引发和诱捕疟疾疫苗
  • 批准号:
    10533280
  • 财政年份:
    2020
  • 资助金额:
    $ 5.9万
  • 项目类别:
Development of an oral liver-targeted prime-and-trap malaria vaccine
开发口服肝脏靶向引发和诱捕疟疾疫苗
  • 批准号:
    10308679
  • 财政年份:
    2020
  • 资助金额:
    $ 5.9万
  • 项目类别:
Establishing the Feasibility of using daily Dried Blood Spots (DBS) to study the Natural History of Low-density Asymptomatic Malaria Infection to Inform Malaria Elimination
建立利用每日干血斑 (DBS) 研究低密度无症状疟疾感染自然史的可行性,为消除疟疾提供信息
  • 批准号:
    9974963
  • 财政年份:
    2020
  • 资助金额:
    $ 5.9万
  • 项目类别:
Establishing the Feasibility of using daily Dried Blood Spots (DBS) to study the Natural History of Low-density Asymptomatic Malaria Infection to Inform Malaria Elimination
建立利用每日干血斑 (DBS) 研究低密度无症状疟疾感染自然史的可行性,为消除疟疾提供信息
  • 批准号:
    10116276
  • 财政年份:
    2020
  • 资助金额:
    $ 5.9万
  • 项目类别:
Liver resident memory for malaria
疟疾的肝脏驻留记忆
  • 批准号:
    10054159
  • 财政年份:
    2018
  • 资助金额:
    $ 5.9万
  • 项目类别:
Liver resident memory for malaria
疟疾的肝脏驻留记忆
  • 批准号:
    10515643
  • 财政年份:
    2018
  • 资助金额:
    $ 5.9万
  • 项目类别:

相似海外基金

Metachronous synergistic effects of preoperative viral therapy and postoperative adjuvant immunotherapy via long-term antitumor immunity
术前病毒治疗和术后辅助免疫治疗通过长期抗肿瘤免疫产生异时协同效应
  • 批准号:
    23K08213
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving the therapeutic immunity of cancer vaccine with multi-adjuvant polymeric nanoparticles
多佐剂聚合物纳米粒子提高癌症疫苗的治疗免疫力
  • 批准号:
    2881726
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
    Studentship
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
  • 批准号:
    10735090
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Evaluation of the Sensitivity to Endocrine Therapy (SET ER/PR) Assay to predict benefit from extended duration of adjuvant endocrine therapy in the NSABP B-42 trial
NSABP B-42 试验中内分泌治疗敏感性 (SET ER/PR) 测定的评估,用于预测延长辅助内分泌治疗持续时间的益处
  • 批准号:
    10722146
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
  • 批准号:
    10933287
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
DEVELOPMENT OF SAS A SYNTHETIC AS01-LIKE ADJUVANT SYSTEM FOR INFLUENZA VACCINES
流感疫苗类 AS01 合成佐剂系统 SAS 的开发
  • 批准号:
    10935776
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
DEVELOPMENT OF SMALL-MOLECULE DUAL ADJUVANT SYSTEM FOR INFLUENZA VIRUS VACCINE
流感病毒疫苗小分子双佐剂体系的研制
  • 批准号:
    10935796
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
A GLYCOLIPID ADJUVANT 7DW8-5 FOR MALARIA VACCINES
用于疟疾疫苗的糖脂佐剂 7DW8-5
  • 批准号:
    10935775
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Adjuvant strategies for universal and multiseasonal influenza vaccine candidates in the context of pre-existing immunity
在已有免疫力的情况下通用和多季节流感候选疫苗的辅助策略
  • 批准号:
    10649041
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
Adjuvant Photodynamic Therapy to Reduce Bacterial Bioburden in High-Energy Contaminated Open Fractures
辅助光动力疗法可减少高能污染开放性骨折中的细菌生物负载
  • 批准号:
    10735964
  • 财政年份:
    2023
  • 资助金额:
    $ 5.9万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了